Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This case report found that a novel botanical treatment halted disease progression and promoted hair regrowth in four patients with lichen planopilaris, indicating potential for use as a safe alternative therapy.

This study reports that among adults with severe alopecia areata taking ritlecitinib, 49% saw hair regrowth within 3 months, increasing to 82% after more than 6 months; treatment satisfaction also rose with longer duration, indicating sustained efficacy and improved quality of life over time.

This study introduces a new device for measuring changes in hair stiffness and lubricity, which can help predict the effects of various hair treatments.

This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.

This study suggests that LOYON® is safe, well tolerated, and effective in reducing scaling from cradle cap in infants and children without causing spot bleedings.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

In this study, intralesional platelet-rich plasma was found to be a beneficial and safe treatment option for oral lichen planus, an inflammatory disease affecting the oral mucosa.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

In this study, researchers developed a new Supported Ionic Liquid Phase palladium catalyst that showed effectiveness in aminocarbonylation reactions for synthesizing pharmaceutical compounds like CX-546 and a precursor of Finasteride, though results were sensitive to substrate variations and prompted palladium leaching concerns.

This study demonstrated that a 12-week treatment with luliconazole-containing shampoo significantly reduced scalp scaling, erythema, and itching in adults with seborrheic dermatitis, achieving high tolerability and progressive symptom improvement without reported intolerance or recurrences.

This report describes an 11-year-old girl with peripilar keratin casts, a condition often underdiagnosed and mistaken for nits, highlighting the usefulness of keratolytic treatments in management.

Treatment improved some symptoms but not all.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This study reports that a patient with rare linear lichen planopilaris experienced complete hair regrowth after 12 weeks of treatment with the antibody ixekizumab, suggesting it as a potential targeted therapy.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This case report describes a 48-year-old male with severe, itchy hypertrophic lichen planus who showed a 90% improvement in lesions following 4 months of treatment with oral acitretin, with no recurrence 6 months posttreatment.

This case report details a 12-year-old boy with Lichen Spinulosus and plantar keratoderma, who responded well to topical treatments including lactic acid, urea, and betamethasone valerate.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study suggests that using a non-medicated, hypo-allergenic scalp clarifying shampoo may improve hair volume and reduce shedding in women with lichen planopilaris and female pattern hair loss.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.